Diabetes & metabolic syndrome · 2025
Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seijas-Amigo José, Salgado-Barreira Ángel, Castelo-Dominguez Rosana, Pérez-Álvarez María Teresa, Ponce-Piñón Belén, Fernández-Silva Marlén, Rodríguez-Barreiro Marta, Pereira-Pía Mercedes, Iglesias-Moreno Jose Manuel, Gago-García Mar, Montáns-García Raquel, Fernandez-Perez Agustina, Fraga-Gayoso Dolores, Fernandez-Montenegro Montse, Riveiro-Barciela Beatriz, Rilla-Villar Natalia, Cardeso-Paredes Begoña, Ribeiro-Ferreiro Marta, Rodriguez-Penas Diego, Cordero Alberto, Rodríguez-Mañero Moisés, González-Juanatey José R, SEVERAL INVESTIGATORS
Аннотация
AIMS: Patients with Type 2 diabetes mellitus face elevated cardiovascular risk. We assessed the effect of GLP-1 receptor agonists on 10-year CVR in a primary prevention cohort.
METHODS: In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers. The primary endpoint was the change in 10-year cardiovascular risk, estimated using the AHA ASCVD Risk Estimator Plus tool at baseline and week 44. Secondary endpoints included weight loss, HbA1c, fasting plasma glucose, and lipid profiles. Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.
RESULTS: In the primary prevention cohort (n = 105), mean 10-year CVR decreased by 3.28 percentage points, a relative reduction of 13.45 % (p < 0.001). Subcutaneous semaglutide showed the greatest weight loss (-8.1 kg), followed by oral semaglutide (-6.5 kg) and dulaglutide (-5.6 kg). HbA1c improved from 8.1 % to 6.6 %, and fasting plasma glucose decreased by 45.8 mg/dL (both p < 0.001).
CONCLUSIONS: GLP-1 receptor agonists reduce 10-year cardiovascular risk in primary prevention and improve metabolic control. Findings support early use in high-risk people with type 2 diabetes.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT05136287.
METHODS: In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers. The primary endpoint was the change in 10-year cardiovascular risk, estimated using the AHA ASCVD Risk Estimator Plus tool at baseline and week 44. Secondary endpoints included weight loss, HbA1c, fasting plasma glucose, and lipid profiles. Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.
RESULTS: In the primary prevention cohort (n = 105), mean 10-year CVR decreased by 3.28 percentage points, a relative reduction of 13.45 % (p < 0.001). Subcutaneous semaglutide showed the greatest weight loss (-8.1 kg), followed by oral semaglutide (-6.5 kg) and dulaglutide (-5.6 kg). HbA1c improved from 8.1 % to 6.6 %, and fasting plasma glucose decreased by 45.8 mg/dL (both p < 0.001).
CONCLUSIONS: GLP-1 receptor agonists reduce 10-year cardiovascular risk in primary prevention and improve metabolic control. Findings support early use in high-risk people with type 2 diabetes.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT05136287.
Предметные рубрики MeSH
AgedFemaleHumansMaleMiddle AgedBiomarkersBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Follow-Up StudiesGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesGlycated HemoglobinHeart Disease Risk FactorsHypoglycemic AgentsPrimary PreventionPrognosisProspective StudiesRecombinant Fusion ProteinsImmunoglobulin Fc FragmentsGlucagon-Like Peptide 1Semaglutide